Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications

Japanese Journal of Ophthalmology

Volumn 54, Issue 3, 2010, Pages 221-226

  Kim, Hyoung Kyun ^a   Chae, Seoung Wan ^b   Woo, Kyung In ^c   Kim, Yoon Duck ^c  

^a Hallym University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Conjunctival melanoma; Conjunctival nevus; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONJUNCTIVA MELANOMA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MITOSIS INDEX; NEVUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; CONJUNCTIVAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77956144921     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-009-0793-1     Document Type: Article

References (30)

1. Seregard S, Koch E. Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol 1992;70:289-296.
2. Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994;78:252-259.
3. Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 1996;234:569-572.
4. Hu DN, Yu G, McCormick SA, Finger PT. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol 2008; 145:418-423.
5. Chau KY, Hui SP, Cheng GP. Conjunctival melanotic lesions in Chinese: comparison with Caucasian series. Pathology 1999;31: 199-201.
6. Lee SB, Au Eong KG, Saw SM, Chan TK, Lee HP. Eye cancer incidence in Singapore. Br J Ophthalmol 2000;84:767-770.
7. Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci 2002;43: 3399-3408.
8. Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 2005;46:75-82.
9. Shields CL. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc 2000;98:471-492.
10. Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol 1985;16:136-143.
11. De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol 1993; 77:624-630.
12. Clark WH Jr, Elder DE, Guerry D 4th, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superfi cial spreading and nodular melanoma. Hum Pathol 1984;15:1147-1165.
13. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115:337-344.
14. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix-metalloproteinase 2 (72 kD Type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996;180: 283-289.
15. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002;95:1963-1970.
16. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle celluveal melanoma. J Pathol 2001;194:201-206.
17. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 2008;39:377-385.
18. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-1630.
19. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
20. Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31: 34-45.
21. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-565.
22. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case control study. Hum Pathol 1992;23:1298-1305
23. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61:6322-6327.
24. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008;6:158-172.
25. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor"regulates the concentration and effi cient activation of progelatinase A. A kinetic study. J Biol Chem 1998;273:871-880.
26. Becker JC, Nikroo A, Brabletz T, Reisfeld RA. DNA loops induced by cooperative binding of transcriptional activator proteins and preinitiation complexes. Proc Natl Acad Sci U S A 1995;92: 9727-9731.
27. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122.
28. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-2298.
29. Møller Sørensen N, Vejgaard Sørensen I, Ørnbjerg Würtz S, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008;43:774-786.
30. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 2000;45:114-121.